Почему борьбы с глаукомой недостаточно: препятствия и ограничения в сохранении зрения

Аннотация

Glaucoma, a significant optic neuropathy, is a principal contributor to irreversible blindness worldwide. Despite effective management of intraocular pressure (IOP), many patients continue to suffer vision loss due to factors beyond IOP. This review investigates the complex nature of glaucoma, encompassing vascular, neurodegenerative, and genetic elements, while also addressing the limitations of existing treatment modalities. Principal obstacles such as late diagnosis, adherence totherapy, and irreversible opticnerve damage, as well as systemic issues like healthcare inequities and socioeconomic influences, are scrutinized. Innovative approaches, including neuroprotective treatments, AI-enhanced diagnostics, personalized medicine, and vision rehabilitation, present potential improvements in patient outcomes. Nevertheless, considerable deficiencies in clinical implementation persist, requiring a fundamental shift inglaucoma management towards prioritizing vision conservation. Keywords: glaucoma, vision preservation, neuroprotection, intraocular pressure, personalized medicine. Introduction. Glaucoma is a neurodegenerative condition resulting in the loss of retinal ganglion cells and optic nerve degeneration, causing irreversible vision loss. Management primarily focuses on intraocular pressure control, the only modifiable risk factor shown to mitigate disease progression. Pharmacological options, like Rho kinase inhibitors, face challenges such as patient adherence and side effects. Surgical methods have shifted towards minimally invasive approaches that require further validation through extensive trials. Despite these developments, some patients experience vision loss even with controlled intraocular pressure, indicating additional factors in disease progression. This has sparked interest in neuroprotective strategies aimed at preserving retinal ganglion cells and optic nerve integrity independently of intraocular pressure management. Although animal studies show promise, no neuroprotective medications have received clinical approval. Future investigations are directed towards IOP-independent therapies, including gene and stem cell interventions, as well as personalized medical strategies to tackle glaucoma's intricate pathophysiology. Understanding glaucoma beyond IOP. Intraocular pressure (IOP) is a pivotal modifiable risk factor in glaucoma treatment, targeting its reduction to avert optic nerve damage. However, disease progression persists in many patients despite adequate IOP management, suggesting additional contributing factors. Vascular parameters, including mean ocular perfusion pressure (MOPP) and blood pressure variability, notably influence normal tension glaucoma (NTG) progression. Research indicates that nocturnal blood pressure declines and MOPP fluctuations are associated with increased visual field impairment, implicating vascular dysregulation in the disease's advancement. Furthermore, glaucoma exhibits shared pathophysiological traits with neurodegenerative disorders such as Alzheimer's and Parkinson's, characterized by apoptosis, disrupted axonal transport, and oxidative stress, which IOP-lowering treatments do not address. Genetic factors also play a role in glaucoma risk, with specific genetic markers correlating with heightened vulnerability. The advancing comprehension of IOP necessitates extensive 464 MAY ANDIJON,2025 monitoring, including ambulatory measurements, to identify fluctuations beyond office settings thaItLcoMrrelaFteAwiNth dYiseAaseNprGogrIeLssiIonKiLndeApeRndeIntKofOavNeraFgeEIORP.ETNhisScoImYprAeheSnsIive perspective emphasizes the integration of vascular, neurodegenerative, and genetic factors into glaucomamanagement strategies toenhancepatient outcomes beyond mere IOP control. Challenges in vision preservation. Preserving vision in glaucoma patients is challenging due to the disease's asymptomatic nature leading to late diagnosis. Glaucoma, a progressive optic neuropathy, involves retinal ganglion cell loss and visual field deterioration, with elevated intraocular pressure as a significant modifiable risk factor. The asymptomatic progression complicates early detection, necessitating careful longitudinal monitoring to discern structural or functional changes. Current therapies target intraocular pressure management but often fail to prevent disease progression, as they do not address underlying optic nerve neurodegeneration. The irreversibility of optic nerve damage complicates treatment, as lost vision cannot be restored. Monitoring progression is difficult due to glaucoma's slow and variable nature, requiring clinical judgment to balance early intervention against overtreatment risks. Patient adherence to IOP-lowering therapies is low, often resulting in medication discontinuation and increased disease progression risk. The emotional and functional burden on patients is considerable, necessitating comprehensive self-management support that encompasses health info